The FDA has cleared the IND filing made by Teva to begin a Phase III trial in patients with chronic congestive heart failure (CHF) using proprietary Mesenchymal Precursor Cells (MPCs) from development partner Mesoblast. The IND was cleared by the FDA within the minimum 30-day period following submission, and patient recruitment is expected to begin shortly. The multi-center trial, which will be conducted by Teva, is planned to enroll approximately 1,700 patients and includes two interim analyse...